Deep-pocketed investors have adopted a bullish approach towards Moderna MRNA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $70,860, and 6 are calls, amounting to $349,752.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $200.0 for Moderna, spanning the last three months.
Volume & Open Interest Trends
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $95.0 to $200.0 in the last 30 days.
Moderna Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | SWEEP | BEARISH | 05/17/24 | $115.00 | $159.8K | 521 | 293 |
| MRNA | CALL | TRADE | BEARISH | 01/17/25 | $200.00 | $53.1K | 1.7K | 258 |
| MRNA | PUT | TRADE | BULLISH | 01/17/25 | $120.00 | $42.9K | 1.0K | 25 |
| MRNA | CALL | TRADE | BULLISH | 04/05/24 | $100.00 | $35.7K | 388 | 50 |
| MRNA | CALL | SWEEP | BEARISH | 03/15/24 | $95.00 | $35.6K | 1.4K | 140 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
Moderna's Current Market Status
- With a volume of 902,286, the price of MRNA is down -1.94% at $104.44.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 49 days.
What Analysts Are Saying About Moderna
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $100.66666666666667.
- Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $125.
- An analyst from Canaccord Genuity persists with their Hold rating on Moderna, maintaining a target price of $91.
- An analyst from HSBC downgraded its action to Reduce with a price target of $86.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
